Drug prices and the Medicare negotiation era

This topic rewards mechanism over outrage, which is why it separates applicants so quickly. Almost everyone knows insulin was expensive. Far fewer can say why a drug discovered in 1921 cost some patients hundreds of dollars a month in 2020, and fewer still can describe what actually changed when Congress intervened.

Here is the version worth holding. American drug prices are set in a market with a peculiar shape: manufacturers set list prices, insurers and pharmacy benefit managers negotiate rebates that most patients never see, and the biggest buyer of all was, by statute, forbidden from negotiating. The Inflation Reduction Act did not overturn that shape. It reached into one part of it — Medicare — and gave the government a seat at the table for a small number of high-spend drugs. Everything interesting about the policy follows from how narrow, and how novel, that intervention is.

Four things stack. Patents and exclusivity give a new drug years without generic competition, which every country accepts as the price of innovation. List prices are set by the manufacturer with no national reference price to anchor them, unlike in almost every peer country. Rebates negotiated by pharmacy benefit managers pull the net price well below the list price, but the discount flows to insurers and plans, while a patient with a deductible or coinsurance pays a share of the list price. And Medicare, created in 1965 and given a drug benefit in 2003, was written with a clause that barred the government from negotiating directly with manufacturers.

That last clause is the one to remember. The Part D drug benefit was designed around private plans competing for enrollees, on the theory that competition would discipline prices better than a federal negotiator. For many generics it did. For brand-name drugs with no competitor, it left the largest purchaser in the country with no leverage at all. Insulin became the emblem because it was old, life-sustaining and made by three companies, and because its list price roughly tripled in a decade while the net price paid by plans rose far less — the gap landing on patients with high deductibles.

The Inflation Reduction Act was signed in August 2022. Its drug provisions phased in over four years, and the dates matter because an interviewer who follows the news will know which parts are live.

An answer that only argues one way is easy to dismantle, and admissions committees do it for sport. Hold both of these at once.

The case for negotiation. Every other wealthy country negotiates or references prices, and none has seen innovation collapse. A purchaser covering tens of millions of people that cannot bargain is not a market; it is a subsidy. The insulin cap in particular addressed a harm that was well documented — patients rationing doses — with a tool that was simple to explain and hard to game.

The case against how it was done. Negotiation with a statutory backstop is closer to price-setting than to bargaining, and the manufacturers’ argument that it will shift research away from drugs likely to be selected is not absurd, even if its scale is contested. The program is also narrow: it touches Medicare, a handful of drugs, and nothing about the rebate chain that leaves commercially insured patients paying a share of list prices. And the largest cost driver in American medicine is not drugs at all, which are around a tenth of health spending; it is hospitals and administration.

This arrives in three shapes. The direct one: "Why are prescription drugs so expensive in the United States?" The opinion one: "Should the government set drug prices?" And the disguised one, where the law is never named but the answer needs it — "What is the biggest problem in American healthcare?" or a scenario about a patient rationing insulin.

For the direct question, walk the chain: patents, list price, rebates, and a purchaser that could not negotiate. For the opinion question, give the structural answer before the personal one. For the scenario, connect the patient in front of you to the mechanism behind the bill.

Start with the Centers for Medicare & Medicaid Services page on the negotiation program, which lists the selected drugs and the effective dates in plain language. Then read one KFF explainer on how Part D works, because the plan design is what determines whether a patient feels any of this. If you want the counterargument in its strongest form, the pharmaceutical industry association publishes it.

Two pieces here give you the surrounding system. How American healthcare is actually structured explains where Medicare sits among employer plans, Medicaid and the exchanges, and the physician shortage is the other access story you will be asked to weigh against cost. For the interview formats themselves, see our US interview guides.